20.63 USD
+0.01 (+0.05%)
20.5 USD
-0.13 (-0.63%)
Taking everything into account, INVA scores 7 out of 10 in our fundamental rating. INVA was compared to 191 industry peers in the Pharmaceuticals industry. INVA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INVA scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, INVA could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year INVA was profitable.
In the past year INVA had a positive cash flow from operations.
Each year in the past 5 years INVA has been profitable.
INVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
INVA's Return On Assets of 8.91% is amongst the best of the industry. INVA outperforms 90.58% of its industry peers.
The Return On Equity of INVA (12.61%) is better than 86.91% of its industry peers.
With an excellent Return On Invested Capital value of 9.43%, INVA belongs to the best of the industry, outperforming 88.48% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for INVA is in line with the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.91% | ||
| ROE | 12.61% | ||
| ROIC | 9.43% |
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
1.3 Margins
INVA has a Profit Margin of 32.78%. This is amongst the best in the industry. INVA outperforms 95.81% of its industry peers.
INVA's Profit Margin has declined in the last couple of years.
INVA's Operating Margin of 43.21% is amongst the best of the industry. INVA outperforms 97.91% of its industry peers.
INVA's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 81.50%, INVA belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 43.21% | ||
| PM (TTM) | 32.78% | ||
| GM | 81.5% |
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), INVA is creating some value.
The number of shares outstanding for INVA has been reduced compared to 1 year ago.
Compared to 5 years ago, INVA has less shares outstanding
INVA has a better debt/assets ratio than last year.
2.2 Solvency
INVA has an Altman-Z score of 3.50. This indicates that INVA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.50, INVA is in the better half of the industry, outperforming 70.68% of the companies in the same industry.
INVA has a debt to FCF ratio of 1.38. This is a very positive value and a sign of high solvency as it would only need 1.38 years to pay back of all of its debts.
INVA has a Debt to FCF ratio of 1.38. This is amongst the best in the industry. INVA outperforms 95.81% of its industry peers.
INVA has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
INVA has a Debt to Equity ratio (0.25) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 1.38 | ||
| Altman-Z | 3.5 |
ROIC/WACC1.12
WACC8.41%
2.3 Liquidity
A Current Ratio of 14.12 indicates that INVA has no problem at all paying its short term obligations.
INVA has a better Current ratio (14.12) than 83.77% of its industry peers.
A Quick Ratio of 13.33 indicates that INVA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 13.33, INVA belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.12 | ||
| Quick Ratio | 13.33 |
3. Growth
3.1 Past
INVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.55%, which is quite impressive.
The earnings per share for INVA have been decreasing by -33.21% on average. This is quite bad
Looking at the last year, INVA shows a quite strong growth in Revenue. The Revenue has grown by 10.14% in the last year.
Measured over the past years, INVA shows a small growth in Revenue. The Revenue has been growing by 6.57% on average per year.
EPS 1Y (TTM)98.55%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%5300%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%20.44%
3.2 Future
INVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 78.97% yearly.
INVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.78% yearly.
EPS Next Y1027.37%
EPS Next 2Y239.14%
EPS Next 3Y129.33%
EPS Next 5Y78.97%
Revenue Next Year12.59%
Revenue Next 2Y10.59%
Revenue Next 3Y9.71%
Revenue Next 5Y9.78%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.06, INVA is valued correctly.
INVA's Price/Earnings ratio is rather cheap when compared to the industry. INVA is cheaper than 85.86% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.54. INVA is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 9.44 indicates a reasonable valuation of INVA.
Based on the Price/Forward Earnings ratio, INVA is valued cheaper than 89.01% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.78. INVA is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | 9.44 |
4.2 Price Multiples
96.86% of the companies in the same industry are more expensive than INVA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, INVA is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.24 | ||
| EV/EBITDA | 5.81 |
4.3 Compensation for Growth
INVA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INVA has a very decent profitability rating, which may justify a higher PE ratio.
INVA's earnings are expected to grow with 129.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y239.14%
EPS Next 3Y129.33%
5. Dividend
5.1 Amount
INVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.63
+0.01 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change3.34%
Ins Owners1.07%
Ins Owner Change3.56%
Market Cap1.54B
Revenue(TTM)388.52M
Net Income(TTM)127.34M
Analysts80
Price Target32.9 (59.48%)
Short Float %7.4%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)85.21%
Min EPS beat(2)50.98%
Max EPS beat(2)119.45%
EPS beat(4)2
Avg EPS beat(4)-52.71%
Min EPS beat(4)-350.17%
Max EPS beat(4)119.45%
EPS beat(8)4
Avg EPS beat(8)-30.46%
EPS beat(12)6
Avg EPS beat(12)-44.02%
EPS beat(16)7
Avg EPS beat(16)-43.24%
Revenue beat(2)2
Avg Revenue beat(2)11.28%
Min Revenue beat(2)6.82%
Max Revenue beat(2)15.75%
Revenue beat(4)4
Avg Revenue beat(4)7.84%
Min Revenue beat(4)3.7%
Max Revenue beat(4)15.75%
Revenue beat(8)8
Avg Revenue beat(8)12.47%
Revenue beat(12)11
Avg Revenue beat(12)11.27%
Revenue beat(16)11
Avg Revenue beat(16)-2.38%
PT rev (1m)-10.91%
PT rev (3m)-21.34%
EPS NQ rev (1m)8.72%
EPS NQ rev (3m)52.71%
EPS NY rev (1m)80%
EPS NY rev (3m)102.57%
Revenue NQ rev (1m)1.69%
Revenue NQ rev (3m)2.06%
Revenue NY rev (1m)4.87%
Revenue NY rev (3m)4.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | 9.44 | ||
| P/S | 3.97 | ||
| P/FCF | 8.24 | ||
| P/OCF | 7.65 | ||
| P/B | 1.53 | ||
| P/tB | 2.07 | ||
| EV/EBITDA | 5.81 |
EPS(TTM)1.37
EY6.64%
EPS(NY)2.19
Fwd EY10.59%
FCF(TTM)2.5
FCFY12.13%
OCF(TTM)2.7
OCFY13.07%
SpS5.2
BVpS13.51
TBVpS9.95
PEG (NY)0.01
PEG (5Y)N/A
Graham Number20.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.91% | ||
| ROE | 12.61% | ||
| ROCE | 12.16% | ||
| ROIC | 9.43% | ||
| ROICexc | 15.37% | ||
| ROICexgc | 22.41% | ||
| OM | 43.21% | ||
| PM (TTM) | 32.78% | ||
| GM | 81.5% | ||
| FCFM | 48.17% |
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
ROICexc(3y)16.17%
ROICexc(5y)24.46%
ROICexgc(3y)28.95%
ROICexgc(5y)34.96%
ROCE(3y)14.67%
ROCE(5y)23.41%
ROICexgc growth 3Y-8.78%
ROICexgc growth 5Y-15.28%
ROICexc growth 3Y-21.15%
ROICexc growth 5Y-17.48%
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 1.38 | ||
| Debt/EBITDA | 1.24 | ||
| Cap/Depr | 36.13% | ||
| Cap/Sales | 3.73% | ||
| Interest Coverage | 16.22 | ||
| Cash Conversion | 96.95% | ||
| Profit Quality | 146.98% | ||
| Current Ratio | 14.12 | ||
| Quick Ratio | 13.33 | ||
| Altman-Z | 3.5 |
F-Score6
WACC8.41%
ROIC/WACC1.12
Cap/Depr(3y)4.13%
Cap/Depr(5y)2.48%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.27%
Profit Quality(3y)320.3%
Profit Quality(5y)247.45%
High Growth Momentum
Growth
EPS 1Y (TTM)98.55%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%5300%
EPS Next Y1027.37%
EPS Next 2Y239.14%
EPS Next 3Y129.33%
EPS Next 5Y78.97%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%20.44%
Revenue Next Year12.59%
Revenue Next 2Y10.59%
Revenue Next 3Y9.71%
Revenue Next 5Y9.78%
EBIT growth 1Y4.12%
EBIT growth 3Y-23.66%
EBIT growth 5Y-7.5%
EBIT Next Year38.24%
EBIT Next 3Y15.74%
EBIT Next 5YN/A
FCF growth 1Y60.93%
FCF growth 3Y-20.27%
FCF growth 5Y-6.46%
OCF growth 1Y72.8%
OCF growth 3Y-19.65%
OCF growth 5Y-6.03%
INNOVIVA INC / INVA FAQ
Can you provide the ChartMill fundamental rating for INNOVIVA INC?
ChartMill assigns a fundamental rating of 7 / 10 to INVA.
What is the valuation status for INVA stock?
ChartMill assigns a valuation rating of 9 / 10 to INNOVIVA INC (INVA). This can be considered as Undervalued.
How profitable is INNOVIVA INC (INVA) stock?
INNOVIVA INC (INVA) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for INVA stock?
The Price/Earnings (PE) ratio for INNOVIVA INC (INVA) is 15.06 and the Price/Book (PB) ratio is 1.53.
What is the expected EPS growth for INNOVIVA INC (INVA) stock?
The Earnings per Share (EPS) of INNOVIVA INC (INVA) is expected to grow by 1027.37% in the next year.